- Home
- BME vs PRTC Comparison
BME vs PRTC Comparison
Compare BME & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BME
- PRTC
- Stock Information
- Founded
- BME 2005
- PRTC 2015
- Country
- BME United States
- PRTC United States
- Employees
- BME N/A
- PRTC N/A
- Industry
- BME Trusts Except Educational Religious and Charitable
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- BME Finance
- PRTC Health Care
- Exchange
- BME Nasdaq
- PRTC Nasdaq
- Market Cap
- BME 525.3M
- PRTC 457.3M
- IPO Year
- BME N/A
- PRTC N/A
- Fundamental
- Price
- BME $40.21
- PRTC $18.47
- Analyst Decision
- BME
- PRTC Buy
- Analyst Count
- BME 0
- PRTC 1
- Target Price
- BME N/A
- PRTC $45.00
- AVG Volume (30 Days)
- BME 34.0K
- PRTC 1.8K
- Earning Date
- BME 01-01-0001
- PRTC 08-28-2024
- Dividend Yield
- BME 6.26%
- PRTC N/A
- EPS Growth
- BME N/A
- PRTC N/A
- EPS
- BME 1.44
- PRTC N/A
- Revenue
- BME N/A
- PRTC $468,000.00
- Revenue This Year
- BME N/A
- PRTC N/A
- Revenue Next Year
- BME N/A
- PRTC $160.00
- P/E Ratio
- BME $28.37
- PRTC N/A
- Revenue Growth
- BME N/A
- PRTC N/A
- 52 Week Low
- BME $35.53
- PRTC $17.00
- 52 Week High
- BME $43.20
- PRTC $34.00
- Technical
- Relative Strength Index (RSI)
- BME 50.67
- PRTC 46.10
- Support Level
- BME $40.01
- PRTC $18.35
- Resistance Level
- BME $40.55
- PRTC $18.89
- Average True Range (ATR)
- BME 0.38
- PRTC 0.43
- MACD
- BME -0.11
- PRTC 0.00
- Stochastic Oscillator
- BME 17.09
- PRTC 26.62
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.
About PRTC PureTech Health plc
PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.